Marketing Models for the Life Sciences Industry

The life sciences industry forms the innovative producer side of therapies in the healthcare industry. The industry has several unique features and is an important part of the economy. The life sciences industry gives rise to interesting research questions, as well as enables new model development to support managerial decision making. The academic marketing literature has produced a sizeable array of decision-support tools for the life science marketers. In this chapter, we present to researchers and managers in the life sciences industry a broad overview of these analytical tools, categorized according to subject areas, and the key managerial insights that have been derived from them. We first present the typical models employed in the following modeling traditions: choice model, count model, learning model, modeling key opinion leaders, diffusion model, sales growth model, and launch model. We then discuss the findings on the role of marketing categorized according to the following decision areas: direct-to-physician promotion, direct-to-consumer advertising, pricing, and product usage adherence. We conclude with a number of areas that we think need more research.

[1]  R. Kravitz,et al.  Request Fulfillment in Office Practice: Antecedents and Relationship to Outcomes , 2002, Medical care.

[2]  Ceren Kolsarici,et al.  Category- versus Brand-Level Advertising Messages in a Highly Regulated Environment , 2010 .

[3]  T. Valente Social network thresholds in the diffusion of innovations , 1996 .

[4]  G. Lilien,et al.  Medical Innovation Revisited: Social Contagion versus Marketing Effort1 , 2001, American Journal of Sociology.

[5]  Sachin Gupta,et al.  An Empirical Model of Drug Detailing: Dynamic Competition and Policy Implications , 2015 .

[6]  W. S. Comanor,et al.  Strategic Pricing of New Pharmaceuticals , 1998, Review of Economics and Statistics.

[7]  Lakshman Krishnamurthi,et al.  The Advantages of Entry in the Growth Stage of the Product Life Cycle: An Empirical Analysis , 1999 .

[8]  Pradeep K. Chintagunta,et al.  New Drug Diffusion when Forward-Looking Physicians Learn from Patient Feedback and Detailing , 2012 .

[9]  M. Wosinska,et al.  Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products , 2002 .

[10]  Harikesh S. Nair,et al.  Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders , 2008 .

[11]  Jacob Goldenberg,et al.  Riding the Saddle: How Cross-Market Communications Can Create a Major Slump in Sales , 2002 .

[12]  M. Kyle,et al.  Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales* , 2002, The Journal of Law and Economics.

[13]  Wei Zhang,et al.  Understanding Responses to Contradictory Information About Products , 2011, Mark. Sci..

[14]  D. Lundin Moral hazard in physician prescription behavior. , 2000, Journal of health economics.

[15]  Anusua Datta,et al.  Effects of Physician‐directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence , 2013, Health economics.

[16]  Qiang Liu,et al.  The Impact of Direct-to-Consumer Advertising of Prescription Drugs on Physician Visits and Drug Requests: Empirical Findings and Public Policy Implications , 2011 .

[17]  Masataka Yamada,et al.  Forecasting with a repeat purchase diffusion model , 1988 .

[18]  Stefan Stremersch,et al.  Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes , 2008, Mark. Sci..

[19]  M. F. Luce,et al.  Understanding High-Stakes Consumer Decisions: Mammography Adherence Following False-Alarm Test Results , 2003 .

[20]  G. Jin,et al.  Direct to Consumer Advertising and Prescription Choice , 2007 .

[21]  Ernst R Berndt,et al.  Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression , 2004, Medical care.

[22]  Peter E. Rossi,et al.  Response Modeling with Nonrandom Marketing-Mix Variables , 2004 .

[23]  F. Bass A new product growth model for consumer durables , 1976 .

[24]  Kurt R. Brekke,et al.  Direct-to-Consumer Advertising in Pharmaceutical Markets , 2005, Journal of health economics.

[25]  Stefan Stremersch,et al.  Health and marketing: The emergence of a new field of research ☆ , 2008 .

[26]  C. Bulte New Product Diffusion Acceleration: Measurement and Analysis , 2000 .

[27]  Shantanu Dutta,et al.  Physicians' Persistence and its Implications for Their Response to Promotion of Prescription Drugs , 2008, Manag. Sci..

[28]  Sridhar Narayanan,et al.  Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions , 2004 .

[29]  Pradeep K. Chintagunta,et al.  Strategic Pricing and Detailing Behavior in International Markets , 2005 .

[30]  M. Ekelund,et al.  Pharmaceutical Pricing in a Regulated Market , 2003, Review of Economics and Statistics.

[31]  Stefan Stremersch,et al.  Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field , 2009 .

[32]  Jae Young Lee,et al.  Social Contagion in New Product Trial and Repeat , 2015, Mark. Sci..

[33]  D. Salkever,et al.  "Generic Entry and the Pricing of Pharmaceuticals" , 1995 .

[34]  Sridhar Narayanan,et al.  Heterogeneous Learning and the Targeting of Marketing Communication for New Products , 2009, Mark. Sci..

[35]  Kurt R. Brekke,et al.  Price Regulation and Parallel Imports of Pharmaceuticals , 2014 .

[36]  J. Hellerstein,et al.  The importance of the physician in the generic versus trade-name prescription decision. , 1998, The Rand journal of economics.

[37]  Pradeep K. Chintagunta,et al.  Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis , 2004 .

[38]  Thomas W. Valente,et al.  Opinion Leadership and Social Contagion in New Product Diffusion , 2011, Mark. Sci..

[39]  P. Leeflang,et al.  Why Do Firms Invest in Consumer Advertising with Limited Sales Response? A Shareholder Perspective , 2011 .

[40]  G. Jin,et al.  The Effect of Prescription Drug Advertising on Doctor Visits , 2005 .

[41]  Puneet Manchanda,et al.  A new multivariate count data model to study multi-category physician prescription behavior , 2011 .

[42]  Leonard J. Parsons,et al.  Analysis of Sales Call Effectiveness , 1981 .

[43]  Jongkuk Lee,et al.  The Timing of Codevelopment Alliances in New Product Development Processes: Returns for Upstream and Downstream Partners , 2015 .

[44]  Ricardo Montoya,et al.  Dynamic Allocation of Pharmaceutical Detailing and Sampling for Long-Term Profitability , 2010, Mark. Sci..

[45]  The effect of customer empowerment on adherence to expert advice , 2014 .

[46]  Tammo H. A. Bijmolt,et al.  Generalizations on the effectiveness of pharmaceutical promotional expenditures , 2008 .

[47]  Sönke Albers,et al.  Personal Selling Elasticities: A Meta-Analysis , 2010 .

[48]  Sriram Venkataraman,et al.  The Relationship between DTCA, Drug Requests and Prescriptions: Uncovering Variation in Specialty and Space , 2012, Mark. Sci..

[49]  Min Ding,et al.  Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector , 2008 .

[50]  S. Dutta,et al.  Portfolios of Interfirm Agreements in Technology-Intensive Markets: Consequences for Innovation and Profitability , 2004 .

[51]  Henry G. Grabowski,et al.  Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.

[52]  Jennifer L. Burton,et al.  Patient empowerment: A cross-disease exploration of antecedents and consequences , 2015 .

[53]  Stephane Jacobzone,et al.  Pharmaceutical Policies in OECD Countries , 2000 .

[54]  Bas Donkers,et al.  Predictably Non-Bayesian: Quantifying Salience Effects in Physician Learning About Drug Quality , 2011, Mark. Sci..

[55]  Füsun F. Gönül,et al.  Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .

[56]  Ying Xie,et al.  The Role of Targeted Communication and Contagion in Product Adoption , 2008, Mark. Sci..

[57]  J. Rizzo,et al.  Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs* , 1999, The Journal of Law and Economics.

[58]  S. Majumdar,et al.  Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study , 2008, BMJ : British Medical Journal.

[59]  D. Strang,et al.  Spatial and Temporal Heterogeneity in Diffusion , 1993, American Journal of Sociology.

[60]  M. Kyle The Role of Firm Characteristics in Pharmaceutical Product Launches , 2006 .

[61]  J. Lanjouw Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry , 2005 .

[62]  C. Sismeiro,et al.  Perception Spillovers across Competing Brands: A Disaggregate Model of how and When , 2008 .

[63]  M S Wilkes,et al.  Direct-to-consumer prescription drug advertising: trends, impact, and implications. , 2000, Health affairs.

[64]  M. Wosinska Direct-to-Consumer Advertising and Drug Therapy Compliance , 2005 .

[65]  M. Kyle,et al.  Intellectual Property Rights and Access to Innovation: Evidence from Trips , 2014 .

[66]  R. Discenza,et al.  Increasing the odds of patient compliance through prescription warning labels. , 1987, Journal of health care marketing.

[67]  Atul Nerkar,et al.  Acquisition Integration and Productivity Losses in the Technical Core: Disruption of Inventors in Acquired Companies , 2006, Organ. Sci..

[68]  Stefan Stremersch,et al.  Social Contagion and Income Heterogeneity in New Product Diffusion: A Meta-Analytic Test , 2004 .

[69]  Carrie M. Heilman,et al.  Determinants of Product-Use Compliance Behavior , 2004 .

[70]  A. Shiell,et al.  Do fee descriptors influence treatment choices in general practice? A multilevel discrete choice model. , 1997, Journal of health economics.

[71]  Andrew A. Signore,et al.  Pharmaceutical Industry Profile , 2005 .

[72]  Richard E. Caves,et al.  Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry , 1991 .

[73]  Sriram Venkataraman,et al.  The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? , 2007, Manag. Sci..

[74]  P. Geoffard,et al.  Therapeutic non-adherence: a rational behavior revealing patient preferences? , 2007, Health economics.

[75]  E. Campbell,et al.  Physician acquiescence to patient demands for brand-name drugs: results of a national survey of physicians. , 2013, JAMA internal medicine.

[76]  T. Bhatia,et al.  Identifying Physician Peer-to-Peer Effects Using Patient Movement Data , 2010 .

[77]  Autonomous regulation and long-term medication adherence in adult outpatients. , 1998 .

[78]  Pradeep K. Chintagunta,et al.  Temporal Differences in the Role of Marketing Communication in New Product Categories , 2005 .

[79]  Lakshman Krishnamurthi,et al.  Analysis of New Product Diffusion Using a Four-Segment Trial-Repeat Model , 1994 .

[80]  E. Berndt,et al.  Demand Effects of Recent Changes in Prescription Drug Promotion , 2003 .

[81]  Y. R. Wang,et al.  The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s , 2003, Health economics.

[82]  C. Winston,et al.  Direct‐to‐Consumer Advertising and the Demand for Cholesterol‐Reducing Drugs* , 2002, The Journal of Law and Economics.

[83]  William B. Vogt,et al.  A Simple Model of Pharmaceutical Price Dynamics* , 2003, The Journal of Law and Economics.

[84]  Mary Frances Luce,et al.  Are Consumers Too Trusting? The Effects of Relationships with Expert Advisers , 2011 .

[85]  Pierre Azoulay,et al.  Do Pharmaceutical Sales Respond to Scientific Evidence , 2002 .

[86]  Chuan He,et al.  Direct-to-Consumer Advertising of Prescription Drugs: A Strategic Analysis , 2009, Mark. Sci..

[87]  Hsien-Ming Lien,et al.  Progress and compliance in alcohol abuse treatment. , 2010, Journal of health economics.

[88]  Jaap E. Wieringa,et al.  Early Marketing Matters: A Time-Varying Parameter Approach to Persistence Modeling , 2010 .

[89]  Marc Fischer,et al.  Patient-or Physician-Oriented Marketing: What Drives Primary Demand for Prescription Drugs? , 2010 .

[90]  Adrian Towse,et al.  Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context , 2012, Health economics.

[91]  Pradeep Chintagunta,et al.  Information, learning, and drug diffusion: The case of Cox-2 inhibitors , 2008 .

[92]  Stefan Stremersch,et al.  Drug Detailing and Doctors' Prescription Decisions: The Role of Information Content in the Face of Competitive Entry , 2016, Mark. Sci..

[93]  Matthew Shum,et al.  An empirical model of learning and patient spillovers in new drug entry , 2004 .

[94]  J. Coleman,et al.  Medical Innovation: A Diffusion Study. , 1967 .

[95]  R. Chandy,et al.  The Impact of Acquisitions on Innovation: Poison Pill, Placebo, or Tonic? , 2005 .

[96]  Frank Windmeijer,et al.  Pharmaceutical Promotion and Gp Prescription Behaviour , 2004, Health economics.

[97]  Mattias Ganslandt,et al.  Parallel imports and the pricing of pharmaceutical products: evidence from the European Union. , 2004, Journal of health economics.

[98]  D. McCaffrey,et al.  Evaluations of care by adults following a denial of an advertisement-related prescription drug request: the role of expectations, symptom severity, and physician communication style. , 2006, Social science & medicine.

[99]  Andrew T. Ching,et al.  The effects of detailing on prescribing decisions under quality uncertainty , 2009 .

[100]  C. Sismeiro,et al.  Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules , 2008 .

[101]  G. Urban,et al.  Information, marketing, and pricing in the U.S. antiulcer drug market. , 1995, The American economic review.

[102]  Annika Herr,et al.  The welfare impact of parallel imports: a structural approach applied to the German market for oral anti-diabetics. , 2014, Health economics.

[103]  R. Kravitz,et al.  How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[104]  I. Cockburn,et al.  Patents and the Global Diffusion of New Drugs , 2014, The American economic review.

[105]  David B. Montgomery,et al.  Estimating Dynamic Effects of Market Communications Expenditures , 1972 .

[106]  C. Croux,et al.  The Global Entry of New Pharmaceuticals: A Joint Investigation of Launch Window and Price , 2011 .

[107]  Ying Xie,et al.  Treatment Effectiveness and Side Effects: A Model of Physician Learning , 2013, Manag. Sci..

[108]  Sriram Venkataraman,et al.  Erratum - The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link? , 2008, Manag. Sci..

[109]  Natalie Mizik,et al.  Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions , 2004, Manag. Sci..

[110]  Gregory S. Carpenter,et al.  Late Mover Advantage: How Innovative Late Entrants Outsell Pioneers: , 1998 .

[111]  R. Kravitz,et al.  Getting to "no": strategies primary care physicians use to deny patient requests. , 2010, Archives of internal medicine.

[112]  Sriram Thirumalai,et al.  Product Recalls in the Medical Device Industry: An Empirical Exploration of the Sources and Financial Consequences , 2011, Manag. Sci..

[113]  M. Gilly,et al.  Gaining Compliance and Losing Weight: The Role of the Service Provider in Health Care Services , 2004 .

[114]  Harikesh S. Nair,et al.  Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations , 2004 .

[115]  D. Vakratsas,et al.  A dual-market diffusion model for a new prescription pharmaceutical , 2008 .